29 students from Sri Chaitanya secure top 100 ranks
Among the top performers are Majid Husain (All India Rank 3), Ujjwal Kesari (AIR 5), Akshat Kumar Chaurasia (AIR 6), and Arnav Nigam (AIR 11) in the Open Category. Other notable ranks include Devdutta Majhi (AIR 16), D Gnana Rutvik Sai (AIR 18), and Vangala Ajay Reddy (AIR 19). Overall, the institution's students bagged three spots in the top 10, seven in the top 20, and 19 in the top 50.
Sushma Boppana, CEO and academic director of the group, said this year's exam format posed new challenges.
"This was a crucial year for competitive exams. The level of difficulty changed, for instance, there were 36 numerical-based questions, which are time-consuming and complex. The pattern is evolving to reflect current academic and problem-solving demands," she said.
Meanwhile, students reflected on their preparation journeys. Arnav Nigam, who scored 316 marks and secured the 11th rank, said managing stress was key. "It's one of the toughest exams, so stress is natural. I worked on handling it better. I used to take frequent short breaks ,10 to 15 minutes, without using my phone or watching television. I'd go for a stroll or simply relax. That helped me stay focused."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
a day ago
- Time of India
Bengaluru lab fails to match woman's blood type to anyone, discovers first human with ultra-rare antigen that could revolutionize medicine
When Routine Surgery Unveiled a Rare Mystery A Blood Sample's Journey India's Rising Role in Rare Blood Research Why CRIB Changes the Game In a remarkable turn of events that is being hailed as a historic medical milestone, a 38-year-old woman from Karnataka has become the first person in the world to be identified with a previously unknown blood group antigen — officially named CRIB. According to a report from Times of India, the discovery, unveiled at the 35th Regional Congress of the International Society of Blood Transfusion (ISBT) in Milan in June 2025, is now being seen as a potential game-changer in the fields of transfusion medicine and organ transplant name CRIB isn't random — it stands for Cromer-India-Bangalore , paying homage to the antigen's family system and the city where this scientific breakthrough took medical mystery began in an unsuspecting operation theatre. Admitted for cardiac surgery in Kolar district, the patient, believed to have the widely common O Rh+ blood group, was expected to receive a standard transfusion. But in a shocking twist, her blood reacted adversely to all compatible O-positive donor should have been a routine procedure soon spiraled into a global medical investigation. With every available unit failing the compatibility test, the hospital escalated the case to the Advanced Immunohematology Reference Laboratory at Rotary Bangalore TTK Blood Centre.'We found her blood was panreactive — it reacted with every single donor sample,' said Dr. Ankit Mathur of the Rotary Centre. 'Even 20 of her closest family members didn't match. That's when we knew this was something the world hadn't seen before.'With local testing hitting a wall, blood samples were sent overseas to the International Blood Group Reference Laboratory (IBGRL) in Bristol, UK. Ten months of meticulous molecular and serological testing later, researchers identified an entirely new antigen under the Cromer (CR) blood group discovery was not just a scientific revelation — it was a collaborative triumph. The CRIB antigen now enters medical history as a reference point for future studies and emergency care cases around the the life-threatening stakes, doctors managed to perform the cardiac surgery without requiring a transfusion — a risky but ultimately successful decision. The woman not only survived but ended up redefining how the world views 'universal' blood isn't the first time India has made headlines in rare blood discoveries. Dr. Mathur notes that India has previously identified and reported cases involving Rh null and In b negative types, which were presented at international platforms. However, CRIB's identification may prove even more significant due to its global further address the rising need for rare donor matches, the Rotary Bangalore TTK Blood Centre, in collaboration with Karnataka State Blood Transfusion Council, ICMR's IIH in Mumbai, and ISBT, has launched a Rare Donor Registry Rare blood groups like CRIB are often difficult to detect and nearly impossible to match in emergencies. By adding a new antigen to global databases, CRIB opens the door to improved transfusion safety protocols, enhanced compatibility testing, and better organ transplant success rates."This is not just a scientific win — it's a humanitarian one," said a representative from ISBT. 'CRIB will help protect lives where standard blood group typing fails.'
Economic Times
a day ago
- Economic Times
Bengaluru lab fails to match woman's blood type to anyone, discovers first human with ultra-rare antigen that could revolutionize medicine
iStock In a groundbreaking discovery, a woman from Karnataka has been identified with a novel blood group antigen, CRIB, unveiled at the ISBT congress in Milan. This finding, a potential game-changer for transfusion medicine and organ transplant safety, emerged after her blood reacted adversely to all compatible donor units during cardiac surgery. (Image: iStock) In a remarkable turn of events that is being hailed as a historic medical milestone, a 38-year-old woman from Karnataka has become the first person in the world to be identified with a previously unknown blood group antigen — officially named CRIB. According to a report from Times of India, the discovery, unveiled at the 35th Regional Congress of the International Society of Blood Transfusion (ISBT) in Milan in June 2025, is now being seen as a potential game-changer in the fields of transfusion medicine and organ transplant safety. The name CRIB isn't random — it stands for Cromer-India-Bangalore, paying homage to the antigen's family system and the city where this scientific breakthrough took place. The medical mystery began in an unsuspecting operation theatre. Admitted for cardiac surgery in Kolar district, the patient, believed to have the widely common O Rh+ blood group, was expected to receive a standard transfusion. But in a shocking twist, her blood reacted adversely to all compatible O-positive donor units. What should have been a routine procedure soon spiraled into a global medical investigation. With every available unit failing the compatibility test, the hospital escalated the case to the Advanced Immunohematology Reference Laboratory at Rotary Bangalore TTK Blood Centre. 'We found her blood was panreactive — it reacted with every single donor sample,' said Dr. Ankit Mathur of the Rotary Centre. 'Even 20 of her closest family members didn't match. That's when we knew this was something the world hadn't seen before.' With local testing hitting a wall, blood samples were sent overseas to the International Blood Group Reference Laboratory (IBGRL) in Bristol, UK. Ten months of meticulous molecular and serological testing later, researchers identified an entirely new antigen under the Cromer (CR) blood group system. The discovery was not just a scientific revelation — it was a collaborative triumph. The CRIB antigen now enters medical history as a reference point for future studies and emergency care cases around the globe. Despite the life-threatening stakes, doctors managed to perform the cardiac surgery without requiring a transfusion — a risky but ultimately successful decision. The woman not only survived but ended up redefining how the world views 'universal' blood types. This isn't the first time India has made headlines in rare blood discoveries. Dr. Mathur notes that India has previously identified and reported cases involving Rh null and In b negative types, which were presented at international platforms. However, CRIB's identification may prove even more significant due to its global implications. To further address the rising need for rare donor matches, the Rotary Bangalore TTK Blood Centre, in collaboration with Karnataka State Blood Transfusion Council, ICMR's IIH in Mumbai, and ISBT, has launched a Rare Donor Registry. Rare blood groups like CRIB are often difficult to detect and nearly impossible to match in emergencies. By adding a new antigen to global databases, CRIB opens the door to improved transfusion safety protocols, enhanced compatibility testing, and better organ transplant success rates. "This is not just a scientific win — it's a humanitarian one," said a representative from ISBT. 'CRIB will help protect lives where standard blood group typing fails.' v
Time of India
3 days ago
- Time of India
Building Trust in Healthcare AI: India's Path from Potential to Practice
New Delhi: As India's healthcare sector grapples with rising patient volumes, workforce shortages and systemic capacity constraints, Artificial Intelligence (AI) is increasingly emerging as a practical and powerful tool to bridge critical gaps. Recent discussions among healthcare leaders and policymakers have spotlighted how AI is no longer just a futuristic concept but a present-day ally for clinicians navigating complex healthcare realities. The recently unveiled Future Health Index (FHI) 2025 India report was marked by an engaging discussion with some of India's leading healthcare experts and advocates. The event underscored how India is now poised to transition from viewing AI as a tool of potential to embracing it as a practical solution in real world healthcare settings. With a special address by H.E. Ms. Marisa Gerards, Ambassador of the Kingdom of the Netherlands to India, Nepal, and Bhutan, the event featured a thought-provoking panel discussion with leading healthcare experts including Mr. Neeraj Jain, Director - Growth Operations, Asia, Middle East and Europe (AMEE), PATH; Dr. Ratna Devi, Board Member at IAPO and CEO of DakshamA Health and Mr. Bharath Sesha, Managing Director, Philips Indian Subcontinent. The session was moderated by Ms. Prathiba Raju, Senior Assistant Editor at ETHealthWorld, The Economic Times Group. According to the India-specific findings in the FHI report, 76% of healthcare professionals believe AI will help improve patient outcomes, while over 80% feel AI can save lives by enabling timely care. These figures point to a growing confidence among India's clinical community in the technology's ability to enhance not replace human decision-making. 'India stands at a pivotal moment in its healthcare transformation,' said Bharath Sesha, Managing Director, Philips Indian Subcontinent. 'There is growing confidence in AI, not just as a tool for efficiency, but as a catalyst for improved outcomes, broader access, and more empowered healthcare professionals. The Future Health Index 2025 findings reaffirm what we've long believed: when applied with purpose, technology can bridge the gap between capability and capacity. Trust in both the technology and the intent behind it is essential to scaling AI in a meaningful way. Cross-sector collaboration is equally critical. By bringing together clinicians, technologists, policymakers, and patients, we can co-create solutions that are clinically relevant, ethically sound, and scalable across India's diverse healthcare ecosystem.' Global best practices suggest that collaboration is key. The development and deployment of AI in healthcare must involve a broad set of stakeholders. This inclusive approach is especially vital in countries like India, where the scale and diversity of the health system present both opportunities and risks. ' Healthcare innovation must be people-centric and globally responsible,' said H.E. Ms. Marisa Gerards, Ambassador of the Kingdom of the Netherlands to India, Nepal and Bhutan. 'During the launch of the 10th edition of Future Health Index 2025 report commissioned by Philips, we had a meaningful discussion with the Indian stakeholders thinking not just about what technology can do, but how it can be applied ethically, equitably, and effectively.' The findings from the report also reveal a broadening acceptance of AI in everyday practice. 72 per cent of professionals say it supports accurate, real-time clinical decision-making, while 75 per cent believe it is particularly valuable for training junior staff and expanding access in underserved areas. 'AI is no longer a choice it's the only viable path to delivering care at scale for a nation of 1.5 billion people,' noted Mr. Neeraj Jain, Director - Growth Operations, Asia, Middle East and Europe (AMEE), PATH. 'But for it to work, our entire ecosystem must be prepared to adopt it responsibly. That means accelerating adoption while ensuring AI tools are developed in close consultation with clinicians, so they are fit for purpose and trusted at the point of care.' While trust in AI is growing, it remains conditional. 67 per cent of healthcare professionals voiced concern over data bias, highlighting the risk of inequities if AI systems are not trained on representative datasets. Questions around legal liability (44%) and defined guardrails for clinical use (45%) also persist. ' Building trust in AI is critical,' said Dr. Ratna Devi, Board Member at IAPO and CEO of DakshamA Health. 'People need clarity on how these tools work and assurance that they are safe and reliable. The doctor–patient ratio in India is unlikely to change dramatically, so AI must be seen as a tool to augment, not replace doctors. It can enhance care delivery, improve efficiency, and help drive change, but it must always complement the human touch.' The FHI 2025 findings also highlight the importance of sustained investment in education and digital capacity-building. Empowering healthcare workers to understand and trust AI, will be essential to mainstream adoption and to ensuring long-term success. As AI moves further into the clinical mainstream, India finds itself at a pivotal moment. With rising readiness among professionals, deepening digital infrastructure, and increasing cross-sectoral momentum - the time to build trust and act is now. Download the full FHI 2025 India Report here Disclaimer - The above content is non-editorial, and ET Healthworld hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
